OS Therapies

OS Therapies Inc

27 Investors

Biotechnology and Pharmaceuticals

Grasonville, MD

OS Therapies Inc. is a publicly traded, clinical-stage biopharmaceutical company dedicated to developing immunotherapies for difficult-to-treat cancers. Their primary focus is on osteosarcoma, a rare bone cancer affecting young people, aiming to address the critical lack of new FDA-approved treatments for this disease in over three decades. The company is advancing its lead candidate through clinical trials while also building a broader pipeline for other solid tumors.

Products & Team

OST-HER2

Cancer ImmunotherapySeed

OST-HER2 is the company's lead product candidate, an off-the-shelf immunotherapy designed to treat osteosarcoma in patients whose tumors express the HER2 protein. It is based on a genetically engineered strain of the bacterium Listeria monocytogenes, which has been altered to safely stimulate a patient's immune system to attack and destroy cancer cells. The product is currently being evaluated in a Phase IIb clinical trial to prevent or delay disease recurrence in patients with recurrent, fully resected pulmonary metastatic osteosarcoma.

Value Proposition

OST-HER2 aims to solve the critical problem of high recurrence rates and lack of effective new treatments for osteosarcoma, a market that has not seen a new FDA-approved drug in over 30 years. It offers a potential new line of defense for young patients at high risk of their cancer returning.

Pain Points

The core customer problem is the severe lack of new and effective treatment options for osteosarcoma, especially for recurrent disease. For over 30 years, there have been no new FDA-approved therapies, leaving patients and clinicians with limited choices and poor prognoses after relapse.

Utilizes a genetically engineered Listeria monocytogenes platformTargets HER2-expressing cancer cellsAdministered as an 'off-the-shelf' immunotherapyGranted Orphan Drug, Fast Track, and Rare Pediatric Disease designations by the FDA